Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, noting an optimistic outlook on the stock.
Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc (NASDAQ: BMRN), engaging with the company on its strategic direction amid leadership changes and the evolving status of its